Core Viewpoint - Hualing Pharmaceutical-B (02552) has seen a significant stock price increase, attributed to the successful commercialization of its core product, the glucose kinase activator (GKA) drug, and its strong revenue growth in the first half of the year [1][2]. Group 1: Company Performance - Hualing Pharmaceutical-B's stock rose over 4% at the close, with a current price of 3.5 HKD and a trading volume of 16.7 million HKD [1]. - The company reported a 110% year-on-year revenue increase in the first half of the year, driven by the commercialization of its GKA product, Mulgrelitin [1]. - The company achieved profitability due to deferred income received from Bayer [1]. Group 2: Product Development - Mulgrelitin, as the first GKA drug globally, was approved for commercialization in 2022, with rapid sales expected after the company regains commercialization rights in 2025 [1]. - Hualing Pharmaceutical-B is developing a second-generation GKA using sustained-release technology and has submitted a clinical application to the FDA [1]. - The GKA field is witnessing a trend of commercialization and internationalization, with Hualing Pharmaceutical-B being a key player, as no other listed companies have clear GKA pipelines [1]. Group 3: Research and Development - A real-world study involving 2,000 type 2 diabetes patients across 80 centers in China confirmed the broad applicability and safety of Mulgrelitin [2]. - New research findings on diabetes remission and cognitive improvement further solidify Hualing Pharmaceutical-B's leading position in GKA research and treatment globally [2].

Summary of Hualing Pharmaceutical Conference Call Company Overview - **Company**: Hualing Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on diabetes treatment Key Points Sales Performance and Projections - Sales for January and February 2025 reached **73 million RMB**, with expectations for the first half of 2025 to be between **180-200 million RMB** [2][3] - The company aims to expand its sales team and targets sales of **700-800 million RMB** in 2026 and over **1 billion RMB** in 2027 to achieve profitability [2][3][4] Research and Development - Core R&D projects include the second-generation GKA, which has completed Phase 1A clinical trials in the U.S. and will start Phase 1B soon, with results expected in Q2/Q3 2026 [2][5] - The company is also expanding indications for the first-generation GKA, focusing on diabetes-related cognitive impairment and MODY 2 [2][5] Market Expansion Plans - Plans to submit a listing application in Hong Kong and Macau in the second half of 2025, which could significantly boost revenue [2][6] - Published research supports the drug's efficacy in improving various health metrics in diabetes patients, aiding in anti-aging claims [2][6] Financial Outlook - Expected to recognize **1.2 billion RMB** in contract liabilities from Bayer, leading to an anticipated profit of over **900 million RMB** for the year [2][8] - Projected gross margin to exceed **65%** by 2027, with sales expenses controlled around **30%** [2][9] Cash Reserves - As of the end of 2024, cash reserves stand at **1.14 billion RMB**, providing a strong financial cushion with no immediate financing needs [2][10] Sales Team Development - After ending the partnership with Bayer, the company built a sales team of **120 members**, led by a former diabetes supervisor from Eli Lilly [3][12] - Plans to expand the sales team to over **200 members** by the end of 2026 to meet increasing market demand [3][12] Patent and Regulatory Status - Patent extension application has been accepted, potentially extending the patent until **2034**, providing long-term market stability [2][14] - The first-generation compound patent is set to expire globally in **2029**, while the second-generation GKA patent is valid until **2042** [2][15] Future Sales and Profitability - Expected peak sales for the domestic single indication to reach approximately **4 billion RMB** between **2030 and 2032** [2][21] - The company anticipates that the sales of diabetes drugs will grow steadily, with a significant increase in revenue as the market expands [2][11] Strategic Focus - The core strategy is to maximize the value of GKA by expanding its indications rather than developing new products [2][19] - The company is preparing for clinical trials in the U.S. for the second-generation GKA, aligning with industry trends and regulatory support [2][20] Conclusion - The company is positioned for significant growth with a robust sales strategy, strong R&D pipeline, and solid financial health, aiming for profitability and market leadership in diabetes treatment.